UK markets closed

Bicycle Therapeutics plc (BCYC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.59-0.03 (-0.13%)
As of 01:39PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 899.29M
Enterprise value 486.11M
Trailing P/E 1.84k
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)21.99
Price/book (mrq)2.53
Enterprise value/revenue 11.68
Enterprise value/EBITDA -3.11

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 32.65%
S&P500 52-week change 325.59%
52-week high 328.91
52-week low 312.54
50-day moving average 323.89
200-day moving average 320.25

Share statistics

Avg vol (3-month) 3408.36k
Avg vol (10-day) 3289.66k
Shares outstanding 538.07M
Implied shares outstanding 636.71M
Float 8N/A
% held by insiders 11.63%
% held by institutions 1105.42%
Shares short (15 Apr 2024) 42.96M
Short ratio (15 Apr 2024) 47.04
Short % of float (15 Apr 2024) 48.58%
Short % of shares outstanding (15 Apr 2024) 47.80%
Shares short (prior month 15 Mar 2024) 42.56M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-162.40%

Management effectiveness

Return on assets (ttm)-23.04%
Return on equity (ttm)-56.13%

Income statement

Revenue (ttm)41.61M
Revenue per share (ttm)1.07
Quarterly revenue growth (yoy)298.90%
Gross profit (ttm)N/A
EBITDA -173.21M
Net income avi to common (ttm)-168.16M
Diluted EPS (ttm)-4.40
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)457M
Total cash per share (mrq)10.74
Total debt (mrq)38.85M
Total debt/equity (mrq)10.91%
Current ratio (mrq)10.42
Book value per share (mrq)8.37

Cash flow statement

Operating cash flow (ttm)-85.09M
Levered free cash flow (ttm)-46.53M